septemb
saw
identif
novel
human
coronaviru
known
middl
east
respiratori
syndrom
coronaviru
merscov
promedmail
zaki
et
al
merscov
betacoronaviru
distinct
genet
relat
sar
sever
acut
respiratori
syndrom
coronaviru
hilgenfeld
peiri
de
wit
et
al
mer
identifi
year
sar
outbreak
spread
across
contin
rais
pandem
concern
continu
concern
pandem
potenti
merscov
hilgenfeld
peiri
de
wit
et
al
assess
anticip
potenti
epidem
spread
merscov
essenti
better
understand
virolog
human
clinic
characterist
possibl
therapeut
prevent
option
epidemiolog
transmiss
anim
interfac
possibl
origin
natur
host
mer
first
identifi
patient
lower
respiratori
diseas
physician
saudi
arabia
subsequ
viru
identifi
character
patient
sputum
sampl
research
saudi
arabia
erasmu
medic
center
netherland
sinc
decemb
laboratoryconfirm
merscov
case
death
across
countri
crude
case
fatal
rate
cfr
report
fig
major
case
death
report
saudi
arabia
world
health
organ
world
health
organizationemro
case
continu
occur
world
health
organizationemro
although
first
known
merscov
case
jordan
confirm
retrospect
sourc
still
unknown
hijawi
et
al
merscov
case
origin
pass
saudi
arabia
infect
like
zoonot
although
origin
transmiss
poorli
understood
dromedari
camel
one
document
sourc
human
zoonot
infect
memish
et
al
systemat
review
merscov
research
conduct
survey
current
understand
merscov
identifi
research
gap
four
major
area
virolog
clinic
characterist
outcom
therapeut
prevent
option
epidemiolog
transmiss
anim
interfac
search
natur
host
merscov
conduct
systemat
literatur
review
use
embas
googl
scholar
medlinepubm
supplement
thomsonreut
web
scienc
databas
identifi
peerreview
publish
articl
merscov
avail
juli
search
articl
publish
onward
sinc
mer
first
identifi
follow
search
term
use
databas
match
titl
googl
scholar
titl
abstract
embas
medlinepubm
topic
web
scienc
novel
coronaviru
novel
coronaviru
emc
novel
coronaviru
erasmu
hcovemc
merscov
pubm
mesh
term
mer
coronaviru
middl
east
respiratori
syndrom
middl
east
respiratori
syndrom
coronaviru
pubm
mesh
term
review
titl
abstract
result
citat
identifi
relev
articl
systemat
review
follow
prisma
guidelin
fig
moher
et
al
nondupl
articl
exclud
opinion
editori
piec
merscov
relat
topic
retriev
fulltext
version
index
citat
inclus
criteria
peerreview
primari
research
articl
merscov
publish
midjuli
inclus
period
updat
ad
uniqu
inform
merscov
knowledg
base
within
least
one
four
key
theme
virolog
clinic
characterist
outcom
therapeut
prevent
option
epidemiolog
transmiss
anim
interfac
search
natur
host
merscov
english
languag
public
englishlanguag
abstract
avail
includ
titl
retriev
uniqu
nondupl
scientif
research
work
relev
merscov
origin
includ
review
base
inclus
criteria
interim
updat
made
articl
prepar
main
laboratori
assay
merscov
molecular
test
detect
viral
rna
serolog
prior
infect
cdc
world
health
organ
revers
transcript
pcr
either
real
time
convent
standard
diagnost
screen
pcr
primer
set
region
upstream
e
gene
upe
frequent
use
confirm
corman
et
al
sensit
report
viral
gene
reaction
upe
copi
specif
approach
use
test
panel
known
coronavirus
clinic
respiratori
sampl
corman
et
al
pcr
report
compar
sensit
specif
upe
corman
et
al
commerci
kit
avail
compar
result
report
corman
et
al
seong
et
al
moham
et
al
sequenc
test
develop
may
better
suit
strain
differenti
target
region
rdrp
rna
polymeras
n
nucleocapsid
gene
corman
et
al
number
public
report
use
corman
et
al
cdc
lu
et
al
anoth
pcr
test
target
spike
region
develop
monitor
circul
merscov
variant
abd
et
al
smit
et
al
type
nucleic
acid
test
also
use
shirato
et
al
immunohistochemistri
ng
et
al
serolog
sampl
usual
screen
use
enzymelink
immunosorb
assay
elisa
reusken
et
al
sampl
elisa
posit
cdc
agenc
formerli
recommend
confirmatori
test
first
immunofluoresc
assay
ifa
gold
standard
plaquereduct
neutral
test
microneutr
cdc
recommend
go
directli
microneutr
assay
cdc
revis
serolog
test
pseudoparticl
neutral
perera
et
al
arraybas
serolog
reusken
et
al
also
develop
unfortun
pitfal
serolog
includ
crossreact
fals
neg
cdc
preliminarili
report
merscov
case
posit
elisa
ifa
later
retract
case
report
due
neg
microneutr
result
breakwel
et
al
consequ
cdc
longer
recommend
ifa
instead
recommend
use
two
differ
elisa
test
microneutr
confirm
cdc
revis
convers
low
wane
antibodi
respons
infect
would
yield
fals
neg
also
report
alshukairi
et
al
choe
et
al
fals
neg
discuss
section
host
respons
clinic
find
describ
review
detail
assiri
et
al
saad
et
al
rasmussen
et
al
world
health
organ
incub
period
day
case
day
assiri
et
al
fever
cough
short
breath
pneumonia
abnorm
chest
radiographi
frequent
note
sign
myalgia
diarrhea
vomit
abdomin
pain
chill
rigor
malais
also
seen
assiri
et
al
drosten
et
al
eckerl
et
al
gueri
et
al
ajlan
et
al
arabi
et
al
faur
et
al
kapoor
et
al
scheuplein
et
al
hunter
et
al
renal
failur
pulmonari
failur
shock
commonli
describ
sever
fatal
case
overal
cfr
world
health
organ
viral
excret
respiratori
tract
document
first
month
ill
memish
et
al
poissi
et
al
spanaki
et
al
greater
viral
load
detect
lower
respiratori
tract
specimen
compar
upper
respiratori
tract
drosten
et
al
gueri
et
al
kapoor
et
al
viral
excret
short
period
report
urin
stool
although
viral
load
low
drosten
et
al
least
one
report
merscov
secondari
case
individu
infect
primari
case
clear
infect
earlier
primari
case
memish
et
al
diseas
outcom
differ
age
comorbid
assiri
et
al
khalid
et
al
saad
et
al
alsahafi
cheng
case
saudi
arabia
occur
among
men
age
older
live
area
lower
rel
humid
high
temperatur
alghamdi
et
al
review
case
saudi
arabia
found
cfr
increas
age
among
year
younger
among
year
older
alsahafi
cheng
mortal
frequent
rapid
individu
comorbid
diabet
chronic
renal
diseas
one
studi
higher
bodi
mass
index
assiri
et
al
altawfiq
et
al
khalid
et
al
saad
et
al
alsahafi
cheng
sever
diseas
associ
higher
viral
load
feikin
et
al
hand
case
report
mer
outcom
vulner
popul
includ
three
case
pregnant
women
one
hivposit
individu
three
document
case
pregnant
women
merscov
infect
one
woman
second
trimest
pregnanc
month
experienc
stillbirth
mother
surviv
payn
et
al
two
women
report
third
trimest
week
present
mer
healthi
infant
deliv
case
although
one
mother
die
despit
interferon
ifn
treatment
malik
et
al
one
recov
despit
sever
symptom
alserehi
et
al
appar
healthi
infect
therefor
possibl
infect
third
trimest
may
associ
better
fetal
outcom
factor
may
critic
matern
outcom
number
small
gener
least
one
publish
case
individu
hivaid
acquir
merscov
shalhoub
et
al
patient
probabl
infect
merscov
hospit
stay
subsequ
shed
viru
day
patient
recov
treatment
shalhoub
et
al
number
studi
immun
function
corman
et
al
zhao
et
al
neutral
antibodi
detect
mani
patient
sever
studi
suggest
neutral
antibodi
induc
infect
appear
protect
corman
et
al
zhao
et
al
suggest
higher
antibodi
titer
may
close
correl
greater
viral
load
consequ
wors
prognosi
zhao
et
al
kinet
respons
may
also
import
antibodi
kinet
studi
patient
south
korea
research
group
later
report
wane
antibodi
titer
patient
followup
found
patient
produc
robust
neutral
igg
antibodi
respons
begin
week
peak
week
delay
respons
gener
correl
less
favor
prognosi
park
et
al
persist
antibodi
gener
seem
follow
similar
pattern
detect
neutral
antibodi
titer
report
patient
month
payn
et
al
howev
result
vari
consider
even
within
group
report
indic
durat
antibodi
respons
well
magnitud
seem
close
correl
diseas
sever
antibodi
could
low
even
absent
mild
asymptomat
infect
alshukairi
et
al
choe
et
al
report
low
wane
antibodi
titer
especi
asymptomat
mildli
symptomat
individu
may
make
serolog
problemat
marker
popul
preval
evid
innat
immun
includ
ifn
cytokin
cellular
immun
presum
killer
cell
may
play
import
role
host
defens
recoveri
faur
et
al
zhao
et
al
zhao
et
al
compar
role
antibodi
cell
human
mer
case
found
survivor
mount
vigor
cell
respons
even
absenc
detect
antibodi
respons
macrophag
also
appear
play
import
role
limit
somewhat
ambigu
data
mous
model
coleman
et
al
human
cell
zhou
et
al
patient
faur
et
al
number
virus
unusu
rest
macrophag
permiss
replic
macrophag
show
antivir
activ
activ
mors
morahan
dendrit
cell
report
produc
ifn
respons
infect
scheuplein
et
al
one
challeng
overcom
effect
viru
host
defens
caveat
much
research
although
done
vitro
may
necessarili
compar
immunolog
result
describ
patient
merscov
report
inhibit
host
innat
immun
lau
et
al
impair
ifn
cytokin
respons
may
mediat
effect
base
assay
cell
mer
patient
faur
et
al
scheuplein
et
al
although
number
patient
small
vitro
studi
shown
merscov
could
downregul
express
ifnstimul
gene
subset
yang
et
al
chemokin
mielech
et
al
anoth
studi
found
merscov
may
caus
delay
induct
proinflammatori
cytokin
togeth
suppress
host
innat
antivir
respons
lau
et
al
viru
replic
human
monocytederiv
macrophag
describ
increas
express
tumor
necrosi
factor
increas
normal
level
interleukin
almost
increas
interleukin
chemokin
increas
even
promin
sarscov
report
zhou
et
al
develop
human
possibl
camel
vaccin
merscov
key
prioriti
given
concern
spread
pandem
potenti
vaccin
develop
long
process
often
driven
econom
modjarrad
much
focu
thu
far
center
identif
residu
within
receptorbind
domain
spike
protein
confer
best
chanc
protect
du
et
al
lan
et
al
et
al
number
antigen
viral
vector
test
laboratori
song
et
al
kim
et
al
replic
defect
fulllength
cdna
clone
merscov
genom
develop
identifi
futur
vaccin
candid
et
al
vaccin
candid
dromedari
camel
also
investig
report
elicit
protect
respons
use
merscov
spike
protein
poxviru
vector
haagman
et
al
special
challeng
develop
mer
vaccin
sporad
natur
human
merscov
infect
difficulti
identifi
suitabl
anim
model
challeng
studi
make
control
trial
difficult
diseas
camel
usual
appear
mild
adney
et
al
reduc
econom
incent
immun
camel
vaccin
could
also
given
combin
requir
vaccin
eg
rabi
suggest
wirblich
et
al
camelpox
suggest
haagman
et
al
correl
protect
durat
immun
also
uncertain
report
strong
antibodi
respons
haagman
et
al
suggest
presenc
neutral
antibodi
may
protect
camel
hemida
et
al
human
corman
et
al
zhao
et
al
wane
antibodi
titer
report
human
recov
merscov
infect
choe
et
al
contrari
report
protect
mice
passiv
transfer
neutral
antibodi
suggest
might
overcom
optim
time
dose
zhao
et
al
research
merscov
vaccin
candid
ongo
least
one
candid
vaccin
progress
phase
human
clinic
trial
modjarrad
cepi
promis
develop
recent
launch
coalit
epidem
prepared
innov
cepi
list
mer
vaccin
one
initi
target
despit
mass
gather
individu
annual
hajj
pilgrimag
khan
et
al
date
result
known
merscov
transmiss
event
barashe
et
al
benkouiten
et
al
gautret
et
al
memish
et
al
aberl
et
al
annan
et
al
confirm
model
estim
hajj
lessler
et
al
two
travel
return
netherland
separ
pilgrimag
umrah
may
found
merscov
kraaijdirkzwag
et
al
mani
travelrel
case
tabul
pavli
et
al
sridhar
et
al
caria
et
al
case
casual
transmiss
outsid
famili
health
care
set
observ
dromedari
camel
document
zoonot
sourc
human
infect
consider
circumstanti
evid
support
cameltohuman
transmiss
includ
evid
camel
human
becom
infect
ident
merscov
azhar
et
al
ferguson
kerkhov
memish
et
al
ident
genom
sequenc
merscov
isol
camel
owner
die
merscov
camel
rhinorrhea
time
ident
merscov
rna
fragment
later
detect
air
camel
barn
azhar
et
al
serolog
suggest
camel
infect
owner
azhar
et
al
critic
suggest
ident
sequenc
may
due
crosscontamin
drosten
et
al
author
maintain
isol
collect
differ
day
process
differ
facil
epidemiolog
investig
found
similar
evid
direction
impli
ferguson
kerkhov
memish
et
al
outbreak
site
viral
genom
sequenc
camel
match
publish
human
one
analysi
merscov
among
camel
show
mani
camel
virus
classifi
clade
correl
human
outbreak
alagaili
et
al
interestingli
three
dromedari
camel
strain
merscov
similar
viral
replic
compet
human
strain
cell
human
respiratori
tract
explant
chan
et
al
evid
suggest
camel
would
appear
involv
crossspeci
transmiss
merscov
although
precis
mechan
frequenc
remain
uncertain
occup
exposur
camel
would
seem
particularli
strong
risk
factor
infect
rel
import
rel
risk
differ
exposur
well
document
hemida
et
al
camel
wide
use
region
varieti
purpos
mani
peopl
contact
camel
exposur
often
invok
nonoccup
primari
case
assess
camel
exposur
complic
vari
sometim
vagu
definit
use
classifi
camel
exposur
multipl
type
possibl
exposur
even
hypothes
camel
exposur
commonli
underreport
gossner
et
al
critic
need
clearer
definit
measur
camel
exposur
standard
methodolog
evid
date
indic
merslik
coronavirus
circul
camel
sinc
least
first
detect
merscov
human
et
al
seroposit
found
consist
african
middl
eastern
camel
sinc
tabl
virolog
evid
merscov
infect
camel
qatar
ferguson
kerkhov
haagman
et
al
raj
et
al
egypt
chu
et
al
ali
et
al
oman
nowotni
kolodziejek
saudi
arabia
hemida
et
al
sudan
elsewher
chu
et
al
ali
et
al
increas
genom
evid
suggest
divers
coronavirus
camel
throughout
middl
east
africa
includ
major
sourc
countri
camel
import
middl
east
crossneutr
merscov
diverg
sequenc
probabl
human
pathogen
chu
et
al
may
explain
high
appar
seroposit
camel
africa
absenc
known
human
case
mer
mainten
viru
camel
popul
remain
open
question
symptomat
merscov
infect
document
calv
adult
camel
adney
et
al
viral
shed
detect
nasal
secret
day
postinocul
merscov
adney
et
al
well
milk
possibl
fece
hemida
et
al
reusken
et
al
camel
milk
suggest
possibl
sourc
infect
human
camel
foal
hemida
et
al
reusken
et
al
van
doremalen
et
al
one
studi
demonstr
ad
merscov
surviv
milk
least
h
although
detect
pasteur
van
doremalen
et
al
possibl
livestock
host
merscov
investig
gener
neg
hemida
et
al
perera
et
al
reusken
et
al
alagaili
et
al
alexandersen
et
al
van
doremalen
et
al
meyer
et
al
one
studi
found
seroposit
alpaca
member
camelid
famili
qatar
reusken
et
al
experiment
infect
alpaca
one
studi
demonstr
upper
respiratori
tract
infect
viral
shed
transmiss
alpaca
adney
et
al
search
origin
natur
host
merscov
continu
bat
speci
across
world
known
host
wide
varieti
coronavirus
includ
betacoronavirus
genu
merscov
belong
anthoni
et
al
corman
et
al
lelli
et
al
memish
et
al
bat
tend
show
greater
coronaviru
divers
mammal
drexler
et
al
anthoni
et
al
consequ
much
research
focus
possibl
origin
merscov
bat
possibl
support
hypothesi
bat
cell
line
merscov
report
replic
cell
line
express
function
human
receptor
viru
bat
cell
line
lack
express
raj
et
al
cai
et
al
possibl
merscov
may
rel
new
introduct
human
phylogenet
analysi
util
complet
partial
complet
merscov
genom
sequenc
saudi
arabian
case
estim
recent
common
ancestor
march
ci
decemb
cotten
et
al
one
studi
analysi
subunit
spike
gene
suggest
merscov
may
arisen
intraspik
recombin
two
ancestr
coronavirus
corman
et
al
viru
isol
bat
although
portion
merscov
rna
sequenc
appar
identifi
bat
insectivor
bat
taphoz
perforatu
egyptian
tomb
bat
saudi
arabia
site
earli
human
case
nucleotid
match
although
nucleotid
rel
wellconserv
rdrp
region
memish
et
al
merslik
coronavirus
includ
close
relat
also
use
receptor
first
identifi
woo
et
al
woo
et
al
lau
et
al
matthew
et
al
wang
et
al
other
identifi
bat
speci
china
matthew
et
al
yang
et
al
mexico
anthoni
et
al
south
africa
ithet
et
al
corman
et
al
uganda
anthoni
et
al
sinc
detect
merscov
larg
bodi
research
amass
evidenc
hundr
uniqu
result
databas
search
viru
rapidli
character
function
human
receptor
swiftli
identifi
speci
cellular
tropism
studi
complement
clinic
investig
laboratori
work
provid
insight
merscov
pathogenesi
observ
research
outbreak
middl
east
south
korea
gener
grow
repositori
clinic
data
basic
epidemiolog
genom
sequenc
studi
evalu
role
humananim
interfac
health
care
set
famili
cluster
travel
merscov
transmiss
furthermor
bat
implic
possibl
origin
merscov
dromedari
camel
shown
like
sourc
mani
human
infect
progress
develop
therapeut
vaccin
although
yet
progress
full
clinic
trial
could
forese
futur
major
reason
undertook
review
determin
gap
still
exist
public
origin
identifi
largest
categori
public
laboratori
basic
scienc
studi
follow
surveil
anim
interfac
clinic
aspect
health
care
therapeut
vaccin
human
transmiss
epidemiolog
one
sparsest
includ
investig
hospit
outbreak
travelrel
case
note
categori
necessarili
exclus
overlap
gener
continu
surveil
merscov
affect
countri
continu
priorit
surveil
human
camel
bat
given
appar
import
serolog
may
reliabl
due
crossreact
possibl
wane
antibodi
virolog
surveil
sequenc
also
attempt
select
specimen
whenev
feasibl
although
role
bat
yet
fulli
elucid
evid
lack
bat
sourc
human
infect
divers
coronavirus
includ
merslik
coronavirus
bat
speci
across
globe
indic
continu
research
ongo
surveil
coronavirus
bat
justifi
lau
et
al
lelli
et
al
yang
et
al
number
key
gap
remain
epidemiolog
includ
transmiss
populationbas
incid
preval
rate
geograph
demograph
distribut
infect
base
limit
human
seropreval
data
far
seem
like
popul
preval
low
baselin
establish
also
clear
whether
seroposit
reliabl
indic
prior
infect
find
variabl
low
antibodi
titer
year
postinfect
choe
et
al
indic
method
tradit
serosurvey
may
requir
reusken
et
al
malik
et
al
serolog
reliabl
rais
question
screen
popul
method
sensit
specif
antibodi
detect
mishra
et
al
well
assay
cellular
immun
zhao
et
al
costlier
difficult
popul
screen
contact
trace
identifi
asymptomat
infect
studi
frequenc
transmiss
limit
mani
infect
health
care
worker
question
could
systemat
studi
rel
littl
known
natur
histori
human
asymptomat
infect
studi
viru
shed
seroconvers
transmiss
asymptomat
infect
need
evid
suggest
secondari
case
lower
averag
cfr
subsequ
link
chain
merscov
infect
may
decreas
sever
exposur
primari
case
still
larg
inferenti
best
camel
appar
often
like
sourc
definit
camel
exposur
vari
prevent
clear
epidemiolog
infer
definit
exposur
methodolog
metric
determin
exposur
clarifi
standard
even
camel
princip
sourc
human
infect
would
still
explain
substanti
portion
primari
human
case
appar
camel
exposur
infect
rais
question
primari
case
acquir
merscov
infect
whether
anim
speci
unidentifi
zoonot
exposur
unrecogn
infecti
person
asymptomat
infecti
individu
environment
contamin
consequ
clarifi
rout
transmiss
remain
crucial
receiv
emphasi
date
compel
evid
direct
humantohuman
transmiss
droplet
secondari
infect
report
often
unclear
health
care
worker
becom
infect
possibl
evid
environment
contamin
fomit
health
care
set
nosocomi
transmiss
close
contact
activ
merscov
case
variou
infect
control
laps
document
rare
specif
event
rout
ben
embarek
van
kerkhov
alraddadi
et
al
van
kerkhov
et
al
rigor
infect
control
therefor
remain
essenti
could
prevent
mani
secondari
case
interim
better
document
identif
specif
laps
led
infect
would
great
valu
understand
mechan
transmiss
one
greatest
knowledg
gap
much
evid
fomit
transmiss
exampl
remain
anecdot
van
kerkhov
et
al
mechan
support
chain
human
merscov
transmiss
need
fulli
evalu
gap
indic
need
addit
research
also
consist
terminolog
clear
definit
although
epidemiolog
literatur
merscov
larg
much
fragment
inconsist
report
often
difficult
deduc
sequenc
infect
relationship
case
specif
exposur
comprehens
consist
databas
registri
prioriti
genom
sequenc
prove
use
sever
respect
genom
sequenc
use
help
determin
viral
circul
ancestri
cotten
et
al
differenti
appar
similar
serolog
crossreact
coronavirus
camel
address
still
unresolv
question
mer
seem
region
limit
mani
camel
import
place
chu
et
al
also
use
reconstruct
transmiss
event
help
establish
chain
infect
assiri
et
al
cotten
et
al
must
note
press
need
rigor
convent
epidemiolog
well
valid
methodolog
approach
might
well
serv
complementari
function
advanc
understand
remain
need
effect
therapeut
vaccin
treatment
remain
symptomat
insuffici
clinic
data
therapeut
option
option
alway
limit
number
develop
approach
systemat
share
protocol
critic
comparison
result
number
drug
vaccin
candid
identifi
may
option
avail
futur
clinic
trial
appear
effort
underway
develop
clinic
trial
base
standard
protocol
need
despit
challeng
present
sporad
natur
case
rel
rariti
clinic
mer
sever
limit
systemat
review
merscov
public
english
english
languag
abstract
elig
inclus
although
case
arabicspeak
area
korea
howev
hundr
english
languag
report
avail
countri
around
world
includ
middl
east
south
korea
minim
concern
second
review
contain
public
index
databas
juli
possibl
public
especi
recent
publish
articl
manuscript
still
product
unintent
exclud
review
updat
literatur
review
period
prepar
articl
minim
number
miss
public
third
gray
literatur
includ
govern
report
technic
document
meet
abstract
although
like
import
find
would
submit
journal
public
emerg
infect
zoonot
origin
mors
unifi
one
health
approach
engag
human
health
livestock
companion
anim
wildlif
environ
sector
crucial
deal
mer
mors
mors
et
al
could
serv
excel
case
studi
epidemiolog
respons
new
zoonot
emerg
infect
